PBN0 Stock Overview
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Alterity Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$3.76 |
| 52 Week High | AU$7.45 |
| 52 Week Low | AU$2.40 |
| Beta | 0.86 |
| 1 Month Change | 0% |
| 3 Month Change | 15.27% |
| 1 Year Change | -47.11% |
| 3 Year Change | -26.95% |
| 5 Year Change | -75.62% |
| Change since IPO | -99.06% |
Recent News & Updates
Recent updates
Shareholder Returns
| PBN0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -4.9% | -1.5% |
| 1Y | -47.1% | -19.9% | 0.9% |
Return vs Industry: PBN0 underperformed the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: PBN0 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| PBN0 volatility | |
|---|---|
| PBN0 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: PBN0 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine PBN0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 12 | David Stamler | alteritytherapeutics.com |
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson’s disease. It is also developing PBT2 that has completed Phase 2a clinical trial to treat Alzheimer’s disease.
Alterity Therapeutics Limited Fundamentals Summary
| PBN0 fundamental statistics | |
|---|---|
| Market cap | €11.93m |
| Earnings (TTM) | -€8.74m |
| Revenue (TTM) | €3.15m |
3.8x
P/S Ratio-1.4x
P/E RatioIs PBN0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PBN0 income statement (TTM) | |
|---|---|
| Revenue | AU$5.15m |
| Cost of Revenue | AU$318.80k |
| Gross Profit | AU$4.83m |
| Other Expenses | AU$19.13m |
| Earnings | -AU$14.30m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0059 |
| Gross Margin | 93.81% |
| Net Profit Margin | -277.57% |
| Debt/Equity Ratio | 0% |
How did PBN0 perform over the long term?
See historical performance and comparison